André N, Leblond P, Verschuur A
Service d'oncologie pédiatrique, hôpital pour enfants de La Timone, AP-HM, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France.
Bull Cancer. 2010 Feb;97(2):191-8. doi: 10.1684/bdc.2009.0960.
Anticancer chemotherapy plays a key role in the treatment of cancer in children. Following its increased efficacy, three children out of four can now be cured. Nevertheless, given the fact that 25% of the children with cancer are not cured and chemotherapy-induced long-term side effects are numerous there is a need to keep developing new agents and new strategies to fight cancer. Moreover studies investigating off-patents drugs should be stimulated in paediatric oncology in order to improve our knowledge of "old" drugs. Here we will review the specificities of children as compared to adults in the context of clinical drug development and pharmacology research in paediatric oncology. Such a research is now encouraged and facilitated by a European regulation as well as by international consortia such as "Innovative Therapies for Children with Cancer" (ITCC).
抗癌化疗在儿童癌症治疗中起着关键作用。随着其疗效的提高,现在四分之三的儿童能够被治愈。然而,鉴于25%的癌症儿童无法治愈,且化疗引起的长期副作用众多,因此有必要持续研发新的抗癌药物和新策略。此外,儿科肿瘤学领域应鼓励开展对专利过期药物的研究,以增进我们对“老”药的了解。在此,我们将在儿科肿瘤学临床药物开发和药理学研究的背景下,探讨儿童与成人相比的特殊性。目前,一项欧洲法规以及诸如“儿童癌症创新疗法”(ITCC)等国际联盟鼓励并推动了此类研究。